The VIVO diagnóstico group takes a further step on its way to becoming the leading company in precision diagnostics in Spain. The company enters the field of genetics, and has just formalised the incorporation of the Genyca group, a laboratory specialising in molecular genetics.
VIVO diagnosis is a company specialising in diagnostic imaging and telemedicineThe new system will be able to combine in vivo and in vitro diagnostics through the use of artificial intelligence and Big Data tools.
To this end, it carries out an analysis based on prediction, prevention and personalisation. For the group, it is essential to identify any signs or probability of change in people's state of health as early as possible and as accurately as possible.
Now, in addition, thanks to GenycaIn addition, molecular genetic diagnostic tests will be incorporated to help study the genome of each individual, also referred to by some industry leaders as the "software of the human body".
However, this is not VIVO diagnostics' first operation on the market. Its journey towards precision diagnostics and service to the public began two years ago with two other operations. strategic acquisitions The following are some of the issues that we set out below.
This clinic leader in breast pathology was the first of these. Dima Clinic has expert breast surgeons, radiologists and oncologists who offer comprehensive breast diagnosis and treatment.
Its experts assess each patient and her risk factors, using both mammography and breast ultrasound and obtaining the analysis of the results in an average of 2-3 days, as in these cases time is of the essence.
Then came Fencea benchmark company in the Andalusian market, and with a strong presence in the world of clinical research.
In addition to mammography and breast ultrasound, its services include magnetic resonance imaging, CT and densitometry, with the aim of offering patients the highest diagnostic quality and reliability.
EN 
ES